tetano
Editor, Senior Moderator
Vaccine. 2012 Oct 18. pii: S0264-410X(12)01471-5. doi: 10.1016/j.vaccine.2012.10.025. [Epub ahead of print]
The economic value of a quadrivalent versus trivalent influenza vaccine.
Lee BY, Bartsch SM, Willig AM.
Source
Public Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, United States. Electronic address: BYL1@pitt.edu.
Abstract
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23084849
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23084849
The economic value of a quadrivalent versus trivalent influenza vaccine.
Lee BY, Bartsch SM, Willig AM.
Source
Public Health Computational and Operations Research (PHICOR), University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, United States. Electronic address: BYL1@pitt.edu.
Abstract
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23084849
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23084849